A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT Study

详细信息    查看全文

• 作者：Elaine S Rogers (1) (2)
  Roderick D MacLeod (1) (3)
  Joanna Stewart (4)
  Stephen P Bird (5)
  Justin WL Keogh (6) (7)
  
• 刊名：BMC Cancer
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：11
• 期：1
• 全文大小：196KB
• 参考文献：1. Tisdale MJ: Cancer anorexia and cachexia. / Nutrition 2001,17(5):438鈥?42. CrossRef
  2. Brennan MF: Uncomplicated Starvation versus Cancer Cachexia. / Cancer Research 1977,37(7 Part 2):2359鈥?364.
  3. Mantovani G, Macci貌 A, Madeddu C, Gramignano G, Serpe R, Massa E, Dess矛 M, Tanca FM, Sanna E, Deiana L, / et al.: Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. / Nutrition 2008,24(4):305鈥?13. CrossRef
  4. Tisdale MJ: Cancer cachexia: Metabolic alterations and clinical manifestations. / Nutrition 1997,13(1):1鈥?. CrossRef
  5. Thomas DR: Distinguishing starvation from cachexia. / Clinics in Geriatric Medicine 2002,18(4):883鈥?91. CrossRef
  6. Inui A: Cancer Anorexia-Cachexia Syndrome: Current Issues in Research and Management. / CA A Cancer Journal for Clinicians 2002,52(2):72鈥?1. CrossRef
  7. Dewys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR, Cohen MH, Douglass JHO, Engstrom PF, Ezdinli EZ, / et al.: Prognostic effect of weight loss prior to chemotherapy in cancer patients. / The American Journal of Medicine 1980,69(4):491鈥?97. CrossRef
  8. Tisdale MJ: Mechanisms of Cancer Cachexia. / Physiological Reviews 2009,89(2):381鈥?10. CrossRef
  9. Bruera E: ABC of palliative care: Anorexia, cachexia, and nutrition. / British Medical Journal 1997,315(7117):1219鈥?222. CrossRef
  10. McMillan DC: An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. / Proceedings of the Nutrition Society 2008,67(03):257鈥?62. CrossRef
  11. Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi Fanelli F: Prevention and treatment of cancer cachexia: New insights into an old problem. / European Journal of Cancer 2006,42(1):31鈥?1. CrossRef
  12. Garcia JM, Cata JP, Dougherty PM, Smith RG: Ghrelin Prevents Cisplatin-Induced Mechanical Hyperalgesia and Cachexia. / Endocrinology 2008,149(2):455鈥?60. CrossRef
  13. Fearon KCH: Cancer cachexia: Developing multimodal therapy for a multidimensional problem. / European Journal of Cancer 2008,44(8):1124鈥?132. CrossRef
  14. McMillan DC, O'Gorman P, McArdle CS: A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. / British Journal of Cancer 1999,79(3/4):495. CrossRef
  15. Marcora SM, Lemmey AB, Maddison PJ: Can progressive resistance training reverse cachexia in patients with rheumatoid arthritis? Results of a pilot study. / The Journal of Rheumatology 2005,32(6):1031鈥?039.
  16. Carroll CC, Dickinson JM, LeMoine JK, Haus JM, Weinheimer EM, Hollon CJ, Trappe TA: Ibuprofen and acetaminophen promote muscle hypertrophy and strength gains during resistance exercise in the elderly. / FASEB J 2008,22(1 Meeting Abstracts):753. 731鈥?53
  17. Keogh JW, MacLeod RD: Body Composition, Physical Fitness, Functional Performance, Quality of Life and Fatigue Benefits of Exercise for Prostate Cancer Patients: A Systematic Review. / Journal of Pain and Symptom Management 2011, in press.
  18. Daley AJ, Crank H, Saxton JM, Mutrie N, Coleman R, Roalfe A: Randomized Trial of Exercise Therapy in Women Treated for Breast Cancer. / Journal of Clinical Oncology 2007,25(13):1713鈥?721. CrossRef
  19. Davis TW, Zweifel BS, O'Neal JM, Heuvelman DM, Abegg AL, Hendrich TO, Masferrer JL: Inhibition of Cyclooxygenase-2 by Celecoxib Reverses Tumor-Induced Wasting. / Journal of Pharmacology and Experimental Therapeutics 2004,308(3):929鈥?34. CrossRef
  20. Lai V, George J, Richey L, Kim HJ, Cannon T, Shores C, Couch M: Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. / Head & Neck 2008,30(1):67鈥?4. CrossRef
  21. Mantovani G, Macci貌 A, Madeddu C, Serpe R, Antoni G, Massa E, Dess矛 M, Panzone F: Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. / Journal of Molecular Medicine 2010,88(1):85鈥?2. CrossRef
  22. Tisdale MJ, Dhesi JK: Inhibition of Weight Loss by Omega-3 Fatty Acids in an Experimental Cachexia Model. / Cancer Research 1990,50(16):5022鈥?026.
  23. Dagnelie P, Bell J, Williams S, Bates T, Abel P, Foster C: Effect of fish oil on cancer cachexia and host liver metabolism in rats with prostate tumors. / Lipids 1994,29(3):195鈥?03. CrossRef
  24. Dewey A, Baughan C, Dean T, Higgins B, Johnson I: Eicosapentaenoic (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. / Cochrane Database of Systematic Reviews 2007., (1):
  25. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KCH: The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. / British Journal of Cancer 1999,81(1):80. CrossRef
  26. Wigmore SJ, Ross JA, Stuart Falconer J, Plester CE, Tisdale MJ, Carter DC, Ch Fearon K: The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer. / Nutrition 1996,12(1 Supplement 1):S27-S30.
  27. Fearon KCH, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, Murray GD: Double-Blind, Placebo-Controlled, Randomized Study of Eicosapentaenoic Acid Diester in Patients With Cancer Cachexia. / J Clin Oncol 2006,24(21):3401鈥?407. CrossRef
  28. Cerchietti LCA, Navigante AH, Peluffo GD, Diament MJ, Stillitani I, Klein SA, Cabalar ME: Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. / Journal of Pain and Symptom Management 2004,27(1):85鈥?5. CrossRef
  29. Lundholm K, Daneryd P, Bosaeus I, K枚rner U, Lindholm E: Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: Effects on survival, metabolism, and function. / Cancer 2004,100(9):1967鈥?977. CrossRef
  30. Cerchietti LCA, Navigante AH, Castro MA: Effects of Eicosapentaenoic and Docosahexaenoic n-3 Fatty Acids From Fish Oil and Preferential Cox-2 Inhibition on Systemic Syndromes in Patients With Advanced Lung Cancer. / Nutrition and Cancer 2007,59(1):14鈥?0. CrossRef
  31. Boddaert MSA, Gerritsen WR, Pinedo HM: On our way to targeted therapy for cachexia in cancer? / Current Opinion in Oncology 2006,18(4):335鈥?40. CrossRef
  32. Mantovani G, Macci贸 A, Madeddu C, Gramignano G, Lusso MR, Serpe R, Massa E, Astara G, Deiana L: A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress. / Cancer Epidemiology Biomarkers & Prevention 2006,15(5):1030鈥?034. CrossRef
  33. Al-Majid S, Waters H: The Biological Mechanisms of Cancer-Related Skeletal Muscle Wasting: The Role of Progressive Resistance Exercise. / Biological Research for Nursing 2008,10(1):7鈥?0. CrossRef
  34. Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Yamaya K, Newton RU: Resistance Training and Reduction of Treatment Side Effects in Prostate Cancer Patients. / Medicine & Science in Sports & Exercise 2006,38(12):2045鈥?052. CrossRef
  35. Temel JS, Greer JA, Goldberg S, Vogel PD, Sullivan M, Pirl WF, Lynch TJ, Christiani DC, Smith MR: A Structured Exercise Program for Patients with Advanced Non-small Cell Lung Cancer. / Journal of Thoracic Oncology 2009,4(5):595鈥?01. 510.1097/JTO.1090b1013e31819d31818e31815 CrossRef
  36. Keogh JW, Shepherd D, Krageloh CU, Ryan C, Masters J, Shepherd G, MacLeod R: Predictors of physical activity and quality of life in New Zealand prostate cancer survivors undergoing androgen-deprivation therapy. / The New Zealand Medical Journal 2010,123(1325):20鈥?9.
  37. Granger CL, McDonald CF, Berney S, Chao C, Denehy L: Exercise intervention to improve exercise capacity and health related quality of life for patients with Non-small cell lung cancer: A systematic review. / Lung Cancer 2011,72(2):139鈥?53. CrossRef
  38. Drummond MJ, Dreyer HC, Fry CS, Glynn EL, Rasmussen BB: Nutritional and contractile regulation of human skeletal muscle protein synthesis and mTORC1 signaling. / Journal of Applied Physiology 2009,106(4):1374鈥?384. CrossRef
  39. Madeddu C, Macci貌 A, Astara G, Massa E, Dess矛 M, Antoni G, Panzone F, Serpe R, Mantovani G: Open phase II study on efficacy and safety of an oral amino acid functional cluster supplementation in cancer cachexia. / Mediterranean Journal of Nutrition and Metabolism 2010,3(2):165鈥?72. CrossRef
  40. Tipton KD, Ferrando AA, Phillips SM, Doyle D, Wolfe RR: Postexercise net protein synthesis in human muscle from orally administered amino acids. / American Journal of Physiology - Endocrinology And Metabolism 1999,276(4):E628-E634.
  41. Rasmussen BB, Tipton KD, Miller SL, Wolf SE, Wolfe RR: An oral essential amino acid-carbohydrate supplement enhances muscle protein anabolism after resistance exercise. / Journal of Applied Physiology 2000,88(2):386鈥?92.
  42. Tipton KD, Rasmussen BB, Miller SL, Wolf SE, Owens-Stovall SK, Petrini BE, Wolfe RR: Timing of amino acid-carbohydrate ingestion alters anabolic response of muscle to resistance exercise. / American Journal of Physiology - Endocrinology and Metabolism 2001,281(2):E197鈥?06.
  43. Tipton KD, Borsheim E, Wolf SE, Sanford AP, Wolfe RR: Acute response of net muscle protein balance reflects 24-h balance after exercise and amino acid ingestion. / American Journal of Physiology - Endocrinology And Metabolism 2003,284(1):E76-E89.
  44. Paddon-Jones D, Sheffield-Moore M, Zhang X-J, Volpi E, Wolf SE, Aarsland A, Ferrando AA, Wolfe RR: Amino acid ingestion improves muscle protein synthesis in the young and elderly. / American Journal of Physiology - Endocrinology And Metabolism 2004,286(3):E321-E328. CrossRef
  45. Katsanos CS, Kobayashi H, Sheffield-Moore M, Aarsland A, Wolfe RR: Aging is associated with diminished accretion of muscle proteins after the ingestion of a small bolus of essential amino acids. / The American Journal of Clinical Nutrition 2005,82(5):1065鈥?073.
  46. Katsanos CS, Kobayashi H, Sheffield-Moore M, Aarsland A, Wolfe RR: A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly. / American Journal of Physiology - Endocrinology And Metabolism 2006,291(2):E381-E387. CrossRef
  47. Fujita S, Dreyer HC, Drummond MJ, Glynn EL, Cadenas JG, Yoshizawa F, Volpi E, Rasmussen BB: Nutrient signalling in the regulation of human muscle protein synthesis. / The Journal of Physiology 2007,582(2):813鈥?23. CrossRef
  48. Aquilani R, Viglio S, Iadarola P, Opasich C, Testa A, Dioguardi FS, Pasini E: Oral Amino Acid Supplements Improve Exercise Capacities in Elderly Patients with Chronic Heart Failure. / The American Journal of Cardiology 2008,101(11 Supplement 1):S104-S110. CrossRef
  49. Solerte SB, Gazzaruso C, Bonacasa R, Rondanelli M, Zamboni M, Basso C, Locatelli E, Schifino N, Giustina A, Fioravanti M: Nutritional Supplements with Oral Amino Acid Mixtures Increases Whole-Body Lean Mass and Insulin Sensitivity in Elderly Subjects with Sarcopenia. / The American Journal of Cardiology 2008,101(11 Supplement 1):S69-S77. CrossRef
  50. Dreyer HC, Drummond MJ, Pennings B, Fujita S, Glynn EL, Chinkes DL, Dhanani S, Volpi E, Rasmussen BB: Leucine-enriched essential amino acid and carbohydrate ingestion following resistance exercise enhances mTOR signaling and protein synthesis in human muscle. / American Journal of Physiology - Endocrinology And Metabolism 2008,294(2):E392-E400. CrossRef
  51. Murphy KT, Lynch GS: Update on emerging drugs for cancer cachexia. / Expert Opinion on Emerging Drugs 2009,14(4):619鈥?32. CrossRef
  52. Evans WJ, Morley JE, Argil茅s J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, / et al.: Cachexia: A new definition. / Clinical Nutrition 2008,27(6):793鈥?99. CrossRef
  53. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/493/prepub
  
• 作者单位：Elaine S Rogers (1) (2)
  Roderick D MacLeod (1) (3)
  Joanna Stewart (4)
  Stephen P Bird (5)
  Justin WL Keogh (6) (7)
  
  1. Department of General Practice and Primary Health Care, University of Auckland, Auckland, New Zealand
  2. Department of Oncology, Auckland City Hospital, Auckland, New Zealand
  3. North Shore Hospice, Takapuna, Auckland, New Zealand
  4. Department of Epidemiology and Biostatistics, University of Auckland, Auckland, New Zealand
  5. School of Human Movement Studies, Charles Sturt University, Bathurst, Australia
  6. Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Australia
  7. Centre for Physical Activity and Nutrition Research, AUT University, Auckland, New Zealand
  
• ISSN：1471-2407

文摘

Background Cancer cachexia is a syndrome of progressive weight loss. Non-small cell lung cancer patients experience a high incidence of cachexia of 61%. Research into methods to combat cancer cachexia in various tumour sites has recently progressed to the combination of agents. The combination of the anti-cachectic agent Eicosapentaenoic acid (EPA) and the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib has been tested in a small study with some benefit. The use of progressive resistance training (PRT) followed by the oral ingestion of essential amino acids (EAA), have shown to be anabolic on skeletal muscle and acceptable in older adults and other cancer groups. The aim of this feasibility study is to evaluate whether a multi-targeted approach encompassing a resistance training and nutritional supplementation element is acceptable for lung cancer patients experiencing cancer cachexia. Methods/Design Auckland's Cancer Cachexia evaluating Resistance Training (ACCeRT) is an open label, prospective, randomised controlled feasibility study with two parallel arms. All patients will be treated with EPA and the COX-2 inhibitor celecoxib on an outpatient basis at the study site. In the experimental group patients will participate in PRT twice a week, followed by the ingestion of essential amino acids high in leucine. A total of 21 patients are planned to be enrolled. Patients will be randomised using 1:2 ratio with 7 patients enrolled into the control arm, and 14 patients into the treatment arm. The primary endpoint is the acceptability of the above multi-targeted approach, determined by an acceptability questionnaire. Discussion To our knowledge ACCeRT offers for the first time the opportunity to investigate the effect of stimulating the anabolic skeletal muscle pathway with the use of PRT along with EAA alongside the combination of EPA and celecoxib in this population. Trial registration Netherlands Trial Register (NTR): ACTRN12611000870954